Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer.

brachytherapy cervical cancer gadolinium-based nanoparticles phase I radiation oncology radiotherapy theragnostics

Journal

ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589

Informations de publication

Date de publication:
24 Jun 2024
Historique:
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: aheadofprint

Résumé

Activated guided irradiation by X-ray (AGuIX) nanoparticles are gadolinium-based agents that have the dual benefit of mimicking the effects of a magnetic resonance imaging (MRI) contrast agent used in a clinical routine and enhancing the radiotherapeutic activity of conventional X-rays (for cancer treatment). This "theragnostic" action is explained on the one hand by the paramagnetic properties of gadolinium and on the other hand by the generation of high densities of secondary radiation following the interaction of ionizing radiation and high-Z atoms, which leads to enhanced radiation dose deposits within the tumors where the nanoparticles accumulate. Here, we report the results of a phase I trial that aimed to assess the safety and determine the optimal dose of AGuIX nanoparticles in combination with chemoradiation and brachytherapy in patients with locally advanced cervical cancer. AGuIX nanoparticles were administered intravenously and appropriately accumulated within tumors on a dose-dependent manner, as assessed by T

Identifiants

pubmed: 38912600
doi: 10.1021/acsnano.3c12537
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Cyrus Chargari (C)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.

Pauline Maury (P)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.

Matthieu Texier (M)

Biostatistics Unit, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Catherine Genestie (C)

Department of Pathology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Philippe Morice (P)

Department of Surgery, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Sophie Bockel (S)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.

Sébastien Gouy (S)

Department of Surgery, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Mouhamadou Ba (M)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Samir Achkar (S)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

François Lux (F)

Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69622 Villeurbanne, France.
Institut Universitaire de France, 75231 Paris, France.

Olivier Tillement (O)

Institut Lumière-Matière, UMR 5306, Université Lyon1-CNRS, Université de Lyon, Villeurbanne Cedex 69622 Villeurbanne, France.

Sandrine Dufort (S)

NH TherAguix SA, 38240 Meylan, France.

Géraldine L E Duc (GLE)

NH TherAguix SA, 38240 Meylan, France.

Olivier Debeaumont (O)

NH TherAguix SA, 38240 Meylan, France.

Christophe Massard (C)

Université Paris-Saclay, CNRS, Institut des Sciences Moléculaires d'Orsay, 91405 Orsay, France.
Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy Cancer Campus, Villejuif 94805, France.
Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
University Paris-Saclay Faculty of Medicine, Le Kremlin, Bicêtre 94270, France.

Amandine Maulard (A)

Department of Pathology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Erika Porcel (E)

Université Paris-Saclay, CNRS, Institut des Sciences Moléculaires d'Orsay, 91405 Orsay, France.

Ratislav Bahleda (R)

Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Samy Ammari (S)

Department of Radiology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Daphné Morel (D)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.

Sophie Espenel (S)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Patricia Pautier (P)

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.

Charlotte Robert (C)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.
Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
University Paris-Saclay Faculty of Medicine, Le Kremlin, Bicêtre 94270, France.

Eric Deutsch (E)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
INSERM1030 Molecular Radiotherapy and Therapeutic Innovation Gustave Roussy Cancer Campus, Villejuif 94805, France.
Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
University Paris-Saclay Faculty of Medicine, Le Kremlin, Bicêtre 94270, France.

Classifications MeSH